NCT01901419

Brief Summary

Hypothermic cardiopulmonary bypass results in peripheral vasoconstriction and heparin trapping. Hypoperfusion and ischemic-reperfusion injury are associated with systemic inflammatory response, while insufficient and delayed neutralization of heparin by protamine may contribute to more blood loss during rewarming stage. Nitroglycerin infusion, an NO-related vasodilator, is an established and effective treatment for unstable angina, myocardial infarction, congestive heart failure, and perioperative hemodynamic management for cardiac surgery. Therefore, we hypothesize that nitroglycerin infusion during rewarming corrects systemic ischemic stress and facilitates heparin neutralization in cardiac surgery.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
80

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jul 2013

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 8, 2013

Completed
2 days until next milestone

First Submitted

Initial submission to the registry

July 10, 2013

Completed
7 days until next milestone

First Posted

Study publicly available on registry

July 17, 2013

Completed
3.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 8, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 8, 2017

Completed
3.5 years until next milestone

Results Posted

Study results publicly available

November 24, 2020

Completed
Last Updated

November 24, 2020

Status Verified

October 1, 2020

Enrollment Period

3.9 years

First QC Date

July 10, 2013

Results QC Date

June 5, 2018

Last Update Submit

October 30, 2020

Conditions

Keywords

nitroglycerincardiopulmonary bypasscardiac surgery

Outcome Measures

Primary Outcomes (11)

  • Plasma Lactate Level, Before Incision

    Plasma Lactate Level, mmol/L, Before Incision

    Before Incision

  • Plasma Lactate Level, Before Start of CPB

    Plasma Lactate Level, mmol/L, Before Start of CPB

    Before Start of CPB

  • Plasma Lactate Level, Release of Aortic Clamp

    Plasma Lactate Level, mmol/L, Release of Aortic Clamp

    Release of Aortic Clamp

  • Plasma Lactate Level, After Protamine Administration

    Plasma Lactate Level, mmol/L, After Cessation of CPB and Protamine Administration

    After Protamine Administration

  • Plasma Lactate Level, Upon Arrival at ICU

    Plasma Lactate Level, mmol/L, Upon Arrival at ICU

    Upon Arrival at ICU

  • Plasma Glucose Level, Before Incision

    Plasma Glucose Level, mg/dL, Before Incision

    Before Incision

  • Plasma Glucose Level, Before Start of CPB

    Plasma Glucose Level, mg/dL, Before Start of CPB

    Before Start of CPB

  • Plasma Glucose Level, Release of Aortic Clamp

    Plasma Glucose Level, mg/dL, Release of Aortic Clamp

    Release of Aortic Clamp

  • Plasma Glucose Level, After Protamine Administration

    Plasma Glucose Level, mg/dL, After Cessation of CPB and Protamine Administration

    After Protamine Administration

  • Plasma Glucose Level, Upon Arrival at ICU

    Plasma Glucose Level, mg/dL, Upon Arrival at ICU

    Upon Arrival at ICU

  • Mean Arterial Blood Pressure ≤ 40 mmHg After Initiation of NTG Infusion

    Mean Arterial Blood Pressure ≤ 40 mmHg After Initiation of NTG Infusion During Rewarming of Cardiopulmonary Bypass

    After Initiation of NTG infusion During Rewarming

Secondary Outcomes (5)

  • Activated Coagulation Time, Before Start of CPB

    Before Start of CPB

  • Activated Coagulation Time, After Protamine Administration

    After Protamine Administration

  • Post-op Dopamine Infusion

    Upon Arrival at ICU

  • Time to Extubation

    Arrival at ICU and Extubation

  • Length of ICU Stay

    Arrival at ICU and Leaving ICU

Other Outcomes (14)

  • Cardiac Index, Before Start of CPB

    Before Start of CPB

  • Cardiac Index, Cessation of CPB

    Cessation of CPB

  • Cardiac Index, After Protamine Administration

    After Protamine Administration

  • +11 more other outcomes

Study Arms (2)

High-dose NTG

EXPERIMENTAL

Nitroglycerin infusion 1-5 mcg/kg/min

Drug: Nitroglycerin infusion

Low-dose NTG

ACTIVE COMPARATOR

Nitroglycerin infusion 0-0.1 mcg/kg/min

Drug: Nitroglycerin infusion

Interventions

Nitroglycerin infusion during rewarming

Also known as: Millisrol
High-dose NTGLow-dose NTG

Eligibility Criteria

Age20 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • elective cardiac surgery

You may not qualify if:

  • heart failure, respiratory failure, asthma attack, uremia, normothermic bypass.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Tri-Service General Hospital

Taipei, 114, Taiwan

Location

Related Publications (2)

  • Piquette D, Deschamps A, Belisle S, Pellerin M, Levesque S, Tardif JC, Denault AY. Effect of intravenous nitroglycerin on cerebral saturation in high-risk cardiac surgery. Can J Anaesth. 2007 Sep;54(9):718-27. doi: 10.1007/BF03026868.

    PMID: 17766739BACKGROUND
  • Masoumi G, Pour EH, Sadeghpour A, Ziayeefard M, Alavi M, Anbardan SJ, Shirani S. Effect of different dosages of nitroglycerin infusion on arterial blood gas tensions in patients undergoing on- pump coronary artery bypass graft surgery. J Res Med Sci. 2012 Feb;17(2):123-7.

    PMID: 23264783BACKGROUND

MeSH Terms

Conditions

Acidosis, Lactic

Condition Hierarchy (Ancestors)

AcidosisAcid-Base ImbalanceMetabolic DiseasesNutritional and Metabolic Diseases

Limitations and Caveats

One patient in NTG group experienced re-sternotomy to check bleeding in the same day and another one expired at the 25th day postoperatively due to mediastinitis with septic shock.

Results Point of Contact

Title
Dr. Tso-Chou Lin
Organization
Department of Anesthesiology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan

Study Officials

  • Tso-Chou Lin, MD

    Tri-Service General Hospital

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: randomized controlled trial
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

July 10, 2013

First Posted

July 17, 2013

Study Start

July 8, 2013

Primary Completion

June 8, 2017

Study Completion

June 8, 2017

Last Updated

November 24, 2020

Results First Posted

November 24, 2020

Record last verified: 2020-10

Data Sharing

IPD Sharing
Will share

all IPD that underlie results in a publication are to be shared starting 6 months after journal publication.

Shared Documents
STUDY PROTOCOL, SAP, CSR
Time Frame
starting 6 months after journal publication.
Access Criteria
all IPD that underlie results in a publication are to be shared via email requests. The corresponding author will review requests and send them the supporting information.

Locations